See also this year's filing and all EDGAR filings for this company.
PDF Report 0001662524_2020_AKCEA_THERAPEUTICS_INC.pdf
Logs
| warning | Missing logo | subcommand.report | {} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.06167718665464382, 'aggregate_val': 452661000, 'exp_sum': 482415000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 181681000, 'ResearchAndDevelopmentExpense': 292852000, 'remainder_Expenses': 7882000}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001662524')"} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001662524, AKCEA THERAPEUTICS INC.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 496,905,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 83,051,000 |
| 2 | PropertyPlantAndEquipmentNet | 5,261,000 |
| 3 | remainder_Assets | 14,033,000 |
| 4 | LiabilitiesCurrent | 41,998,000 |
| 5 | LiabilitiesNoncurrent | 14,248,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 181,681,000 |
| 9 | ResearchAndDevelopmentExpense | 292,852,000 |
| 10 | remainder_Expenses | -21,872,000 |
| 11 | remainder_Revenues | 488,543,000 |
| 12 | remainder_NetIncome | 4,890,000 |
| 13 | remainder_ComprehensiveNetIncome | 329,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 599,250,000 |
| 1 | Liabilities | 56,246,000 |
| 2 | Expenses | 452,661,000 |
| 3 | Revenues | 488,543,000 |
| 4 | StockholdersEquity | 543,004,000 |
| 5 | NetIncome | 40,772,000 |
| 6 | ComprehensiveNetIncome | 40,936,500 |
| 7 | BaseVar | 800,959,500 |
| 8 | EconomicCapitalRatio | 2.97 |
Edgar->Model Mapping
Feature Distribution
Change over Time
